Thrombosis Adviser
This website is intended to provide information to an international audience outside the USA and UK
Sitemap
- Vascular Adviser
- For Patients and Carers
- Knowledge Base
- Latest in Thrombosis
- Thrombosis Digest
- 2022
- ESC 2022 Congress Highlights
- International Society on Thrombosis and Haemostasis (ISTH) Congress 2022 Newsletter
- International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) 2022
- Your older patients with atrial fibrillation: Are you missing the broader picture?
- EHRA 2022 Congress Highlights
- Extended treatment for recurrent VTE: Protecting your patients for as long as they need
- The use of NOACs in the extended management of cancer‑associated thrombosis
- Protecting elderly patients with atrial fibrillation
- 2021
- Preserving kidney function in patients with atrial fibrillation: What do the new data say?
- Bayer symposium highlights from the ESC congress 2021
- Protecting vulnerable patients with VTE: Choose a guideline-recommended therapy that has been thoroughly tested
- Ensuring protection for patients with cancer-associated thrombosis
- International Society on Thrombosis and Haemostasis Conference 2021 newsletter
- Patient preference: How can it help to reduce the burden of thrombosis in patients with cancer-associated thrombosis?
- Stroke prevention in older patients: How can you protect those who need it most?
- International Conference on Thrombosis and Hemostasis Issues in Cancer 2021
- 2020
- When is the right time to start thinking about renal function in patients with AF?
- Thrombosis Adviser at the European Society of Cardiology Congress 2020
- Extended Treatment for VTE: Tailoring Treatment for Patients Who Need it
- Patients with diabetes and atrial fibrillation: How can the risk of cardiovascular death be reduced?
- Managing anticoagulation during the COVID-19 pandemic
- Supporting the treatment of patients with low-risk pulmonary embolism at home
- The importance of real-world evidence: A look at stroke prevention in atrial fibrillation
- Keeping it simple: Single drug approaches to VTE treatment
- The importance of preserving kidney function in atrial fibrillation
- Where next in cancer-associated thrombosis
- Time for a change? Switching anticoagulants in patients with AF or VTE
- High-risk patients with atrial fibrillation: The importance of protection
- Understanding the risk of VTE recurrence: Who needs extended anticoagulation?
- ESC Heart and Stroke Conference: Highlights from Bayer 24–25 January 2020
- Venous protection in 2019: A year in review
- Stroke prevention in patients with AF in 2019: A year in review
- 2019
- Improving AF Detection
- Dosing Schemas of the NOACs for VTE Treatment
- VTE Treatment in Challenging Patient
- High-risk patients with atrial fibrillation: Spotlight on diabetes
- High-risk patients with atrial fibrillation: Spotlight on renal impairment
- Making connections: Stroke risk in patients with multiple co-morbidities
- VTE-CAT: Reducing the burden of injections
- Paediatric patients with VTE: Protecting the most challenging population
- ESC Heart and Stroke Conference Highlights
- ISTH congress highlights from Bayer July 2019
- PE ESC 2019 Guidelines
- ThrombosisAdviser at the European Society of Cardiology Congress 2019
- ThrombosisAdviser at the European Society of Cardiology Congress 2019: Focus on Atrial Fibrillation
- 2018
- 2022
- Real-World Evidence
- Thrombosis Digest
- Tools and Resources
- Newsletter Subscribe Form
- Thrombosis Adviser
- For Patients and Carers
- Knowledge Base
- CAD
- PAD
- FAQ
- The Basics
- Understanding arterial thrombosis
- Burden of atherosclerosis
- Managing atherosclerosis
- How are patients with coronary artery disease (CAD) currently managed?
- How are patients with peripheral artery disease (PAD) currently managed?
- When do patients with peripheral artery disease (PAD) need revascularization?
- What medications are needed following a peripheral revascularization procedure?
- What is dual pathway inhibition?
- How can outcomes be improved in patients with coronary artery disease (CAD)?
- How can outcomes be improved in patients with peripheral artery disease (PAD)?
- How do co-morbidities affect the management of atherothrombosis with the COMPASS regimen?
- Risk factors
- What patients may ask
- Latest in Vascular Protection
- Adviser’s Pick
- 2022
- 2021
- Boosting confidence in preventing recurrent thrombotic events in patients with peripheral artery disease following revascularization
- When should dual pathway inhibition be stopped in patients with symptomatic PAD following peripheral revascularization?
- Antithrombotic protection after lower-extremity revascularization: Can clopidogrel be used alongside DPI?
- 2020
- Thrombotic risk after endovascular revascularization
- Enhanced vascular protection for high-risk patients: What’s your best option?
- Patients with chronic PAD – What can be done to reduce the risk of cardiovascular and limb events?
- Patients undergoing lower extremity revascularization
- The ACC.20/WCC Virtual Experience
- From stable CAD to CCS
- Optimizing vascular protection in high-risk patients: What do the 2019 ESC guidelines say?
- Vascular protection in 2019
- 2019
- Adviser’s Pick
- Tools & Resources
Copyright © Bayer AG |
Updated date 10/10/2022
This website is intended to provide information to an international audience outside the USA and UK.
